Skip to content

NASDAQ · mid · thesis board

RVMD Revolution Medicines

RAS(ON) tri-complex inhibitors

View race

Thesis

Editorial summary — not a primary filing

RAS(ON) inhibitors targeting hard oncogenic drivers including EGFR-related resistance contexts.

Next gate

2027-04-01EstimatedPh2 readout

Dose / combo update

231 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~12 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~608d)100%
Days to gate (231d)38%
Show math

$1.4B cash ÷ $70M/mo burn ≈ 608 days. Source: curated SEC quarter figures.

Cash $1.4B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved
Secondary assets (1)
  • RAS(ON) inhibitor CRC · Ph1 · colorectal-cancer

Rivals in this race

Open race →
AZNApprovedokMRKApprovedokSMMTFiledok

Risks

  • Novel MoA safety
  • Combination strategy
  • Capital needs
  • Competitive RAS field

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05786924as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01